BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

742 related articles for article (PubMed ID: 18281540)

  • 1. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma.
    Lee MJ; Yu GR; Park SH; Cho BH; Ahn JS; Park HJ; Song EY; Kim DG
    Clin Cancer Res; 2008 Feb; 14(4):1080-9. PubMed ID: 18281540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
    Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
    J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The predictive ability of serum alpha-fetoprotein for hepatocellular carcinoma is linked with the characteristics of the target population at surveillance.
    Huo TI; Hsia CY; Chu CJ; Huang YH; Lui WY; Wu JC; Lee PC; Chi CW; Lee SD
    J Surg Oncol; 2007 Jun; 95(8):645-51. PubMed ID: 17530668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma.
    Miura N; Maeda Y; Kanbe T; Yazama H; Takeda Y; Sato R; Tsukamoto T; Sato E; Marumoto A; Harada T; Sano A; Kishimoto Y; Hirooka Y; Murawaki Y; Hasegawa J; Shiota G
    Clin Cancer Res; 2005 May; 11(9):3205-9. PubMed ID: 15867214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection of alpha-fetoproteins mRNA and melanoma antigen-1 mRNA in peripheral blood of patients with hepatocellular carcinoma and its clinical significance].
    Yang SZ; Dong JH; Zhu J; Li K; Zhang Y
    Zhonghua Wai Ke Za Zhi; 2004 Sep; 42(17):1060-3. PubMed ID: 15498320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas.
    Long J; Lang ZW; Wang HG; Wang TL; Wang BE; Liu SQ
    Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):296-305. PubMed ID: 20525558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
    Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y
    Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
    Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L
    J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
    Zinkin NT; Grall F; Bhaskar K; Otu HH; Spentzos D; Kalmowitz B; Wells M; Guerrero M; Asara JM; Libermann TA; Afdhal NH
    Clin Cancer Res; 2008 Jan; 14(2):470-7. PubMed ID: 18223221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients.
    Cedrone A; Covino M; Caturelli E; Pompili M; Lorenzelli G; Villani MR; Valle D; Sperandeo M; Rapaccini GL; Gasbarrini G
    Hepatogastroenterology; 2000; 47(36):1654-8. PubMed ID: 11149026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined serum hepatoma-specific alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma.
    Wu W; Yao DF; Yuan YM; Fan JW; Lu XF; Li XH; Qiu LW; Zong L; Wu XH
    Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):538-44. PubMed ID: 17085339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma.
    Kim J; Ki SS; Lee SD; Han CJ; Kim YC; Park SH; Cho SY; Hong YJ; Park HY; Lee M; Jung HH; Lee KH; Jeong SH
    Am J Gastroenterol; 2006 Sep; 101(9):2051-9. PubMed ID: 16848813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of Wiskott-Aldrich syndrome protein family verprolin-homologous protein 2 correlated with poor prognosis of hepatocellular carcinoma.
    Yang LY; Tao YM; Ou DP; Wang W; Chang ZG; Wu F
    Clin Cancer Res; 2006 Oct; 12(19):5673-9. PubMed ID: 17020969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
    Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
    Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis.
    Wang Y; Liu YH; Mai SJ; He LJ; Liao YJ; Deng HX; Guan XY; Zeng YX; Kung HF; Xie D
    J Gastroenterol Hepatol; 2010 Jun; 25(6):1123-8. PubMed ID: 20594228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma.
    Li XM; Tang ZY; Qin LX; Zhou J; Sun HC
    J Exp Clin Cancer Res; 1999 Dec; 18(4):511-7. PubMed ID: 10746978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients.
    Jin-no K; Tanimizu M; Hyodo I; Nishikawa Y; Hosokawa Y; Endo H; Doi T; Mandai K; Ishitsuka H
    Cancer; 1998 Apr; 82(7):1260-7. PubMed ID: 9529017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma.
    Hayasaka A; Suzuki N; Fujimoto N; Iwama S; Fukuyama E; Kanda Y; Saisho H
    Hepatology; 1996 Nov; 24(5):1058-62. PubMed ID: 8903375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma.
    Kondo M; Yamamoto H; Nagano H; Okami J; Ito Y; Shimizu J; Eguchi H; Miyamoto A; Dono K; Umeshita K; Matsuura N; Wakasa K; Nakamori S; Sakon M; Monden M
    Clin Cancer Res; 1999 Dec; 5(12):4005-12. PubMed ID: 10632332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.